Month: July 2020

RICHMOND, Va., July 30, 2020 (GLOBE NEWSWIRE) — Kinsale Capital Group, Inc. (NASDAQ:KNSL) reported net income of $30.3 million, $1.33 per diluted share, for the second quarter of 2020 compared to $13.8 million, $0.63 per diluted share, for the second quarter of 2019. Net income was $35.3 million, $1.56 per diluted share, for the first half of 2020 compared to $32.5 million, $1.49 per diluted share, for the first half of 2019.Net operating earnings(1) were $19.1 million, $0.84 per diluted share, for the second quarter of 2020 compared to $12.4 million, $0.57 per diluted share, for the second quarter of 2019. Net operating earnings(1) were $36.4 million, $1.60 per diluted share, for the first half of 2020 compared to $26.3 million, $1.21 per diluted share, for the first half of 2019.Highlights for the second quarter and first half...

Provides Update on CPI-006 Phase 1 COVID-19 StudyConference Call Today at 4:30 p.m. ET / 1:30 p.m. PTBURLINGAME, Calif., July 30, 2020 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and announced financial results for the second quarter ended June 30, 2020.“In the second quarter, we advanced each of our three clinical oncology programs, highlighted by the presentation of new data at ASCO on the identification of a refined biomarker that enriches for responding patients with renal cell cancer treated with our lead candidate, ciforadenant,” said Richard A. Miller, M.D.,  president and chief executive officer of Corvus. “Based on this data, we are planning to meet with the U.S. Food & Drug Administration (FDA) to discuss the initiation...

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat presentation at the virtual William Blair Biotech Focus Conference 2020 on Thursday, August 6, at 2 p.m. EDT.The live webcast of the presentation will be accessible from the Media & Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for at least...

PITTSBURGH, July 30, 2020 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies using its scalable PATrOL™ platform to address genetic diseases, announced today that Dietrich Stephan, Chief Executive Officer of NeuBase, will participate in a virtual fireside chat at the BTIG Virtual Biotechnology Conference 2020, being held on August 10 – 11.About NeuBase TherapeuticsNeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities...

YARDLEY, Pa., July 30, 2020 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the second quarter 2020 and corporate updates, before market open on Tuesday, August 4, 2020.Company to Host Conference CallMembers of the Company’s leadership team will host a conference call to discuss financial results and corporate updates, including its launch of XHANCE®. The call is scheduled to start at 8:00 a.m. Eastern Time on Tuesday, August 4, 2020.To participate on the conference call, please dial (866) 916-4761 from the U.S. or +1 (409) 216-6496 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until Tuesday, August 11,...

NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 6, 2020. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.A live webcast of the call will be available on the Company’s website at www.siga.com under the ‘Events & Presentations’ tab in the Investor Relations section, or by clicking here. Participants may also access the call, by dialing 877-407-6184 for domestic callers or 201-389-0877 for international callers. Please log in approximately 5-10 minutes prior to the scheduled start time.A...

TUCSON, Ariz., July 30, 2020 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced three of its previously released Research Use Only (RUO) assays are now available for use with the Thermo Fisher Scientific Ion Torrent Ion S5 next-generation sequencing (NGS) platform.With the release of the HTG EdgeSeq Precision Immuno-Oncology Panel, the HTG EdgeSeq Mouse mRNA Tumor Response Panel, and HTG EdgeSeq Autoimmune Panel, the entire HTG RUO profiling assay menu is now available on both the Illumina and the Thermo Fisher Scientific NGS platforms.“We continue to see interest in our European market for our RUO profiling assays on both the Illumina and Thermo Fisher NGS platforms,” said Jean Claude Gerard, Senior Vice President, European...

DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12th, at 2:20p.m. ET.The presentation will be webcast live and may be accessed by visiting the “Investors” section of the Company’s website under the “Events and Presentations” tab at www.nabriva.com. A replay of the webcast will be available for 90 days.About Nabriva TherapeuticsNabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development...

ROCKVILLE, Md., July 30, 2020 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and reported financial results for the quarter ended June 30, 2020.“We are excited about the momentum we have built to date in 2020. We have presented promising initial clinical data at ASCO from the MGD013 and MGC018 programs. We have defined a potential registration path for flotetuzumab and we have received FDA clearance to initiate clinical testing of our novel antibody-drug conjugate targeting ADAM9 being co-developed with ImmunoGen. Furthermore, we were able to extend our cash runway into 2023,” said Scott Koenig, M.D., Ph.D., President...

PrologueIMPACT EXCEPTIONNEL DU COVID-19 EN FRANCE AU 2EME TRIMESTRE 2020BAISSE DU CA EN FRANCE DE 34,4% A 10,1 M€CROISSANCE HORS DE FRANCE DE 5,2% A 6,9 M€CROISSANCE DES ACTIVITES CLOUD DE 16,9%ACTIVITE EN BAISSE DE -22,6% AU 2EME TRIMESTRE 2020 A 16,98 M€Le groupe Prologue a enregistré, au 2ème trimestre 2020, un chiffre d’affaires de 16,98 M€ en baisse de -22,6%. L’impact du Covid-19 aura été de nature très différente selon les métiers et les régions.  IMPACT EXCEPTIONNEL DU COVID-19 EN FRANCE DANS LA FORMATIONAu cours du 2ème trimestre 2020, la formation a été de loin l’activité la plus impactée du groupe par la crise sanitaire liée au Covid-19, qui l’a contrainte à fermer l’ensemble de ses 35 centres en France du 16 mars jusqu’à début juin. Dans ce contexte exceptionnel, le groupe a réussi à mettre très rapidement en œuvre des solutions...